---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-24-000061"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2024-07-11T23:59:59+00:00"
generated_at: "2026-05-31T21:45:56.013341+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akebia terminates Vafseo license with CSL Vifor, sets royalty payments and buy-down option

## Summary
- License agreement terminated immediately for business reasons; Akebia regains full U.S. marketing rights for Vafseo.
- Akebia to repay $40M working capital fund via quarterly tiered royalties of 8-14% of net sales through May 2028.
- Settlement royalties: high single-digit % on net sales up to $450M, mid-single % above; buy-down option from July 2027.
- Amended $55M Kreos loan facility to include covenants linked to the termination agreement.
- Royalty payments commence July 1, 2025; minimum true-up milestones of $10M, $20M, $40M by 2026-2028.

## SEC filing metadata
- accession: 0001517022-24-000061
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2024-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000061/0001517022-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702224000061/akba-20240710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-24-000061
- JSON: https://secwatch.observer/filing/0001517022-24-000061.json
- Plain text: https://secwatch.observer/filing/0001517022-24-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.